Press Releases
Domain Therapeutics grants Prexton Therapeutics an exclusive option to license and develop mGluR4 PAMs for Parkinson s Disease
Domain Therapeutics S.A. announced today that Domain Therapeutics grants Prexton Therapeutics (Geneva, Switzerland) an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease. The chemical series...
Press Releases
Almac Successfully Completes Knowledge Transfer Partnership with Queens University with Highest Accolade
Almac is pleased to announce the successful completion of the Knowledge Transfer Partnership (KTP) with Queens University Belfast, to develop, improve and embed bioprocesses in order to facilitate the delivery of novel products for its biocatalysis business. ...
Press Releases
BASi Launches Culex NxT Next Generation In Vivo Automated Sampling System
BASi (Bioanalytical Systems, Inc.) today announced the launch of Culex® NxT, the latest generation of the Company’s proprietary in vivo automated sampling system. The Company is now taking orders for Culex NxT and expects to begin shipping in...
Press Releases
Celator® Pharmaceuticals Enrolls First Patient in Its Phase 3 Study of CPX-351 in Untreated High-Risk Acute Myeloid Leukemia
Celator Pharmaceuticals today announced that the first patient has been treated in its Phase 3, multicenter, randomized, open-label clinical trial of CPX-351 (cytarabine:daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy (“7+3”) as first-line therapy in patients 60-75...
Press Releases
Wireless Physiological Monitoring System a Boon for Dialysis Patients
A wireless physiological monitoring system designed by the Department of Biomedical Engineering (BME) of National Cheng Kung University (NCKU), southern Taiwan, has proved to increase medical efficiency and safety for dialysis patients. BME was...
Press Releases
Oncodesign and the Laboratory for Neurobiology and Gene Therapy at the KU Leuven enter into a research collaboration for advancing drug discovery efforts with...
Oncodesign, a drug discovery company and oncology pharmacology service provider and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the department of neurosciences at the KU Leuven, an expert academic group exploring the roles of LRRK2 and...
Press Releases
Adaptimmune Announces Preliminary Results from an Early Phase Trial of Gene Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
Adaptimmune today announces the release of preliminary results from an early phase clinical study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells. Lead investigators for the study presented today in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read